/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Transcode Therapeutics Inc Share Price Today: Live Updates & Key Insights

Transcode Therapeutics Inc share price today is $9, up -3.54%. The stock opened at $8.96 against the previous close of $9.31, with an intraday high of $9.04 and low of $8.785.

Transcode Therapeutics Inc Share Price Chart

style
pb-0

Transcode Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Transcode Therapeutics Inc Share Price Performance

$9 -0.0354(-3.54%) RNAZ at 23 Mar 2026 03:03 PM Biotechnology
Lowest Today 8.785
Highest Today 9.04
Today’s Open 8.96
Prev. Close 9.31
52 Week High 22.03
52 Week Low 6.08
Day’s Range: Low 8.785 High 9.04
52-Week Range: Low 6.08 High 22.03
1 day return -
1 Week return -7.16
1 month return -6.2
3 month return +11.56
6 month return -14.51
1 year return +1229.71
3 year return -96.44
5 year return -99.78
10 year return -

Transcode Therapeutics Inc Institutional Holdings

DRW Securities, LLC 1.28

Vanguard Institutional Extnd Mkt Idx Tr 0.71

Fidelity Extended Market Index 0.39

Citigroup Inc 0.17

Spartan Extended Market Index Pool F 0.13

Fidelity Series Total Market Index 0.13

Tower Research Capital LLC 0.10

Spartan Total Market Index Pool G 0.06

Fidelity Total Market Index 0.06

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

Royal Bank of Canada 0.00

Advisor Group Holdings, Inc. 0.00

Blackstone Alternative Multi-Strategy I 0.00

ACT Capital Management, LLC 0.00

Federation des caisses Desjardins du Quebec 0.00

FMR Inc 0.00

SouthState Bank Corp 0.00

The Goldman Sachs Group Inc 0.00

UBS Group AG 0.00

Transcode Therapeutics Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Transcode Therapeutics Inc Fundamentals

Market Cap 8.23 M

PB Ratio 5.6909

PE Ratio 0.0

Enterprise Value 2.34 M

Total Assets 7.29 M

Volume 14240

Transcode Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-19592604 -19.6M, FY22:-35129936 -35.1M, FY21:-6938469 -6.9M, FY20:-2738330 -2.7M, FY19:-764143 -0.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-4781 -0.0M, Q2/2025:-13443 -0.0M, Q1/2025:-51174 -0.1M, Q3/2024:null 0.0M, Q2/2024:-142835 -0.1M

Quarterly Net worth Q3/2025:-4856051 -4.9M, Q2/2025:-4276502 -4.3M, Q1/2025:-12085413 -12.1M, Q3/2024:-2321387 -2.3M, Q2/2024:-5190814 -5.2M

About Transcode Therapeutics Inc & investment objective

Company Information TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Transcode Therapeutics Inc FAQs

What is the share price of Transcode Therapeutics Inc today?

The current share price of Transcode Therapeutics Inc is $9.

Can I buy Transcode Therapeutics Inc shares in India?

Yes, Indian investors can buy Transcode Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Transcode Therapeutics Inc shares in India?

You can easily invest in Transcode Therapeutics Inc shares from India by:

Can I buy fractional shares of Transcode Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Transcode Therapeutics Inc?

Transcode Therapeutics Inc has a market cap of $8.23 M.

In which sector does Transcode Therapeutics Inc belong?

Transcode Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Transcode Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Transcode Therapeutics Inc?

The PE ratio of Transcode Therapeutics Inc is N/A and the PB ratio is 5.69.